Tandem Diabetes (TNDM) Adds Peyton Howell to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Tandem Diabetes (TNDM) Misses Q2 EPS by 21c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus, 3Q Revenues Outlook Below Consensus
July 30, 2020 4:21 PM EDTTandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.45), $0.21 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $109.2 million versus the consensus estimate of $87.15 million.
We achieved our highest quarterly sales, successfully completed our first acquisition, and executed multiple meaningful agreements in support of our longer-term objectives in the second quarter, said John Sheridan,... More
